Closed End Fund Advisors Inc. Invests $498,000 in abrdn Life Sciences Investors $HQL

Closed End Fund Advisors Inc. bought a new position in shares of abrdn Life Sciences Investors (NYSE:HQL) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 29,706 shares of the company’s stock, valued at approximately $498,000. Closed End Fund Advisors Inc. owned 0.10% of abrdn Life Sciences Investors at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in HQL. Royal Bank of Canada raised its stake in shares of abrdn Life Sciences Investors by 53.3% during the 1st quarter. Royal Bank of Canada now owns 73,475 shares of the company’s stock worth $934,000 after buying an additional 25,542 shares during the period. NewEdge Advisors LLC raised its stake in shares of abrdn Life Sciences Investors by 43.1% during the 1st quarter. NewEdge Advisors LLC now owns 32,500 shares of the company’s stock worth $412,000 after buying an additional 9,785 shares during the period. First Trust Advisors LP raised its stake in shares of abrdn Life Sciences Investors by 112.2% during the 2nd quarter. First Trust Advisors LP now owns 35,321 shares of the company’s stock worth $452,000 after buying an additional 18,674 shares during the period. Raymond James Financial Inc. raised its stake in shares of abrdn Life Sciences Investors by 20.3% during the 2nd quarter. Raymond James Financial Inc. now owns 375,960 shares of the company’s stock worth $4,816,000 after buying an additional 63,429 shares during the period. Finally, Clough Capital Partners L P acquired a new position in shares of abrdn Life Sciences Investors during the 2nd quarter worth approximately $318,000. 32.21% of the stock is owned by institutional investors and hedge funds.

abrdn Life Sciences Investors Stock Down 1.9%

Shares of HQL stock opened at $16.94 on Friday. The stock has a 50 day simple moving average of $17.42 and a 200-day simple moving average of $17.07. abrdn Life Sciences Investors has a 1-year low of $12.34 and a 1-year high of $18.46.

abrdn Life Sciences Investors Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Thursday, May 21st will be paid a $0.56 dividend. This represents a $2.24 annualized dividend and a yield of 13.2%. The ex-dividend date of this dividend is Thursday, May 21st.

abrdn Life Sciences Investors Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.